Novo Nordisk A/S (NVO · NYSE)
NVO · MARKET VIEW
Market view · as of Jun 29, 2026
Revenue (TTM)
$327.80B
+24.0% YoY
Gross margin
83.2%
EPS (latest q)
$6.63
vs $6.96 est · miss
52-wk position
39.2%
-29.9% vs 52w high · +5.6% 1mo
Price (last ~year)
Novo Nordisk reported strong financial momentum with 24.0% year-over-year revenue growth and a 67.1% increase in earnings, posting $96.82 billion in revenue and $48.56 billion in net income for the quarter ending March 31, 2026. The company recently secured UK approval for an oral version of its weight-management drug Wegovy and continues to advance its hemophilia portfolio, while maintaining a $212.80 billion market capitalization. Shares are trading at $48.07, reflecting a 30.8% gain over the last three months.
Valuation
- Market cap
- $212.80B
- P/E
- 11.56
- PEG
- 3.555
- P/B
- 6.9
- P/S
- 0.649
- EV/EBITDA
- 8.52
- Beta
- 0.349
- Analyst target
- $46.86
Quality & returns
- Gross margin
- 83.2%
- Operating margin
- 61.6%
- Profit margin
- 37.2%
- ROE
- 71.4%
- ROA
- 19.3%
Price movement
- Last
- $48.07
- 1-month
- +5.6%
- 3-month
- +30.8%
- RSI (14)
- 74
- vs SMA200
- +2.7%
- 52-wk position
- 39.2% -29.9% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-03-31 | $96.82B | $59.62B | $48.56B | $69.21B |
| 2025-12-31 | $79.14B | $31.74B | $26.89B | $39.75B |
| 2025-09-30 | $74.98B | $23.68B | $20.01B | $33.27B |
| 2025-06-30 | $76.86B | $33.45B | $26.50B | $43.60B |
Recent news
- Bullish Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig · 2026-06-26
- Bullish Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig · 2026-06-26
- Neutral HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners · 2026-06-26
- Neutral Hims' obesity drug business may get boost as employers drop coverage · 2026-06-26
- Somewhat-Bullish HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners · 2026-06-25
- Somewhat-Bullish Novo Nordisk (CPSE:NOVO B) Wins UK Approval For Oral Wegovy With Wider Consumer Ripple Effects · 2026-06-25
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)